EUVIMEDEUVIMED entdecken
Crossref

Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations

Shanni Vaismann, Nili Stein, Liat Dizengoff, Amir Warwar, Shoshan Perek, Ibraheem Zoabi, Walid Saliba, Meir Preis

Thrombosis and Haemostasis · 01.01.2025 · 125 (01) · 082-084

DOI: 10.1055/a-2347-4338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.01.2025. Verfasst von Shanni Vaismann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Severe factor XI (FXI) deficiency is reported to have prevalence of 1:450 within the Ashkenazi Jewish community.[ 1 ] More modest FXI deficiency has been estimated to be more common at 1:10,000–50,000.[ 2 ] FXI is part of the coagulation cascade and is essential in the propagation of the coagulation cascade and thrombin generation.[ 3 ] [ 4 ] There is a poor correlation between decreased FXI activity and bleeding tendency except during interventions in areas with high fibrinolytic activity.[ 5 ] It has been postulated that an underlying cardiovascular benefit may protect the FXI-deficient subjects from developing an adverse cardiovascular event or venous thromboembolism. In the largest cohort published to date, we have demonstrated that inherited FXI deficiency confers significant cardiovascular benefit.[ 6 ] However, some of these patients require anticoagulation or antiplatelet therapy for primary or secondary prevention of cardiovascular complications. It is unknown whether the use of these medications increases the risk for bleeding in the setting of decreased FXI levels.[ 7 ] Authors' Contribution V.S., N.S., W.S., and M.P. designed the study. V.S., L.D., A.W., S.P., and I.Z. collected the data. N.S., W.S., and M.P. analyzed the data. M.P. and N.S. wrote the manuscript. Publication History Received: 12 June 2024 Accepted: 15 June 2024 Accepted Manuscript online: 18 June 2024 Article published online: 04 July 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Stuttgart · New York

Autor:innen und Institutionen

  • Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel.
  • Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.

Zitieren

APA

Vaismann, S., Stein, N., Dizengoff, L., Warwar, A., Perek, S., Zoabi, I., Saliba, W., & Preis, M. (2025). Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations. Thrombosis and Haemostasis, 125(01), 082-084. https://doi.org/10.1055/a-2347-4338

Vancouver

Vaismann S, Stein N, Dizengoff L, Warwar A, Perek S, Zoabi I, et al. Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations. Thrombosis and Haemostasis. 2025;125(01):082-084. doi:10.1055/a-2347-4338

BibTeX
@article{Vaismann2025,
  author = {Vaismann, Shanni and Stein, Nili and Dizengoff, Liat and Warwar, Amir and Perek, Shoshan and Zoabi, Ibraheem and Saliba, Walid and Preis, Meir},
  title = {Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {01},
  pages = {082--084},
  doi = {10.1055/a-2347-4338}
}
Kostenlos starten →